Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial

Irene E. G. van Hellemond, Carolien H. Smorenburg, Petronella G. M. Peer, Astrid C. P. Swinkels, Caroline M. Seynaeve, Maurice J. C. van der Sangen, Judith R. Kroep, Hiltje de Graaf, Aafke H. Honkoop, Frans L. G. Erdkamp, Franchette W. P. J. van den Berkmortel, Wilfred K. de Roos, Sabine C. Linn, Alexander L. T. Imholz, Maaike de Boer, Vivianne C. G. Tjan-Heijnen*, Dutch Breast Canc Res Grp BOOG

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Web of Science)
Original languageEnglish
Pages (from-to)675-685
Number of pages11
JournalBreast Cancer Research and Treatment
Volume180
Issue number3
DOIs
Publication statusPublished - Apr 2020

Keywords

  • Breast cancer
  • Tamoxifen
  • Aromatase inhibitor
  • Bone health
  • Osteoporosis
  • Bisphosphonates
  • Survival
  • Bone metastases
  • Distant recurrence-free survival
  • ZOLEDRONIC ACID
  • POSTMENOPAUSAL WOMEN
  • IN-VITRO
  • THERAPY
  • CELLS
  • RISK
  • CHEMOTHERAPY
  • METASTASIS
  • MECHANISMS
  • CLODRONATE

Cite this